Danaher Co. (NYSE:DHR) Shares Sold by Moody Lynn & Lieberson LLC

Moody Lynn & Lieberson LLC decreased its stake in shares of Danaher Co. (NYSE:DHR) by 6.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,980 shares of the conglomerate’s stock after selling 390 shares during the period. Moody Lynn & Lieberson LLC’s holdings in Danaher were worth $1,373,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Decker Retirement Planning Inc. bought a new position in shares of Danaher in the fourth quarter valued at approximately $31,000. Teachers Insurance & Annuity Association of America acquired a new stake in Danaher in the third quarter worth approximately $39,000. MidAtlantic Capital Management Inc. bought a new position in Danaher during the 3rd quarter valued at $40,000. FSA Wealth Management LLC bought a new stake in shares of Danaher in the 3rd quarter worth $50,000. Finally, Darwin Wealth Management LLC acquired a new stake in shares of Danaher in the third quarter valued at $55,000. 79.05% of the stock is currently owned by institutional investors.

Danaher Stock Performance

Shares of DHR opened at $245.95 on Friday. Danaher Co. has a 52 week low of $225.42 and a 52 week high of $281.70. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. The company has a market capitalization of $177.65 billion, a PE ratio of 46.94, a PEG ratio of 4.43 and a beta of 0.83. The company’s 50 day moving average price is $235.33 and its 200 day moving average price is $253.45.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be paid a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.44%. The ex-dividend date is Friday, December 27th. Danaher’s dividend payout ratio (DPR) is presently 20.61%.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. UBS Group lowered their target price on Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a report on Wednesday, October 23rd. TD Cowen lifted their price objective on shares of Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a research note on Wednesday, October 23rd. Bank of America raised shares of Danaher from a “neutral” rating to a “buy” rating and set a $290.00 target price for the company in a research note on Friday, December 13th. Royal Bank of Canada decreased their price target on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 23rd. Finally, Stephens reiterated an “overweight” rating and set a $315.00 price objective on shares of Danaher in a research report on Wednesday, October 23rd. Six equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $285.55.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.